• Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in their lifetime
• Previous studies have shown that VETMEDIN^® could help improve the survival time and quality of life for dogs with congestive heart failure due to myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM)
• The new VETMEDIN^® Solution offers pet owners a convenient, liquid oral treatment option for those dogs that prefer a liquid

Boehringer Ingelheim, a global leader in animal health, launched VETMEDIN^® Solution, the first oral solution approved by the U.S. Food and Drug Administration (FDA) for the management of congestive heart failure (CHF) in dogs due to MMVD or DCM.

Unfortunately, heart disease in dogs is common, affecting approximately 10 percent of dogs in their lifetime.¹ Most frequently, dogs are affected by myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM), both which may progress to CHF, characterized by the inability of the heart to effectively pump blood throughout the body.

Now pet owners have a convenient, new management option to support the hearts of dogs with CHF: a liquid version of VETMEDIN^®, one of the leading canine cardiology medications in the world. Previous studies have shown that VETMEDIN^® could help increase the survival time and quality of life in dogs due to MMVD or DCM.

IMPORTANT SAFETY INFORMATION: VETMEDIN^® Solution (pimobendan oral solution) and VETMEDIN^® (pimobendan) Chewable Tablets

VETMEDIN® Solution (pimobendan oral solution) and VETMEDIN® (pimobendan) Chewable Tablets are for use in dogs with clinical evidence of heart failure only and should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. For more information, see full prescribing information for Vetmedin Solution or see full prescribing information for Vetmedin Chewable Tablets or visit Vetmedinclinic.com

"We continue to deliver new innovations rooted in robust clinical evidence to help more pets," said Daniel Watkins, VP US Pet Business, Boehringer Ingelheim. "We know some dogs and pet owners may prefer a liquid medication, especially for smaller dogs. With VETMEDIN^® Solution, an easy-to- use liquid formulation, we can help more dogs with heart disease have longer survival and live better lives."

VETMEDIN^® Solution, now available in the U.S., provides the same dual mode of action as VETMEDIN^® Chewable Tablets. The flavorless, twice-daily liquid oral solution should be administered directly into the dog's mouth.

Since VETMEDIN^® was first introduced 25 years ago, dogs and their owners around the world have enjoyed more than 1 million years of additional life to love.⁴ VETMEDIN^® Chewable Tablets are approved for the management of the signs of mild, moderate, or severe CHF in dogs due to clinical MMVD or DCM. VETMEDIN^® Chewable Tablets are indicated for use with concurrent therapy for congestive heart failure (e.g., furosemide, etc.) as appropriate on a case-by-case basis.

Boehringer Ingelheim also offers VETMEDIN^®-CA1 (pimobendan), which has FDA conditional approval for use in dogs with Stage B2 preclinical MMVD – which may enable a delay in the onset of heart failure symptoms.

For more information, visit www.boehringer-ingelheim.com/animal-health.

IMPORTANT SAFETY INFORMATION: VETMEDIN^® Solution (pimobendan oral solution) and VETMEDIN^® (pimobendan) Chewable Tablets

VETMEDIN^® Solution and VETMEDIN^® Chewable Tablets are for use in dogs with clinical evidence of heart failure only. The most common side effects reported in field studies were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. VETMEDIN^® Solution and VETMEDIN^® Chewable Tablets should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons